Background Reducing hospital readmission offer potential benefits for patients, providers, payers, and policymakers to improve quality of healthcare, reduce cost, and improve patient experience. We investigated effectiveness of remdesivir in reducing 30-day COVID-19-related readmission during the Omicron era, including older adults and those with underlying immunocompromising conditions. Methods This retrospective study utilized the US PINC AI Healthcare Database to identify adult patients discharged alive from an index COVID-19 hospitalization between December 01, 2021 and February 29, 2024. Odds of 30-day COVID-19-related readmission to the same hospital were compared between patients who received remdesivir vs those not, after balancing characteristics of two groups using inverse probability of treatment weighting (IPTW). Analyses were stratified by maximum supplemental oxygen requirement during index hospitalization. Results Of 326,033 patients hospitalized for COVID-19 during study period, 210,586 patients met the eligibility criteria. Of these, 109,551 (52%) patients were treated with remdesivir. After IPTW, lower odds of 30-day COVID-19-related readmission were observed in patients who received remdesivir vs those who did not, in the overall population (3.3% vs 4.2%, respectively; odds ratio [95% confidence interval]: 0.78 [0.75–0.80]), elderly population (3.7% vs 4.7%, respectively; 0.78 [0.75–0.81]), and those with underlying immunocompromising conditions (5.3% vs 6.2%, respectively; 0.86 [0.80–0.92]). These results were consistent irrespective of supplemental oxygen requirements. Conclusions Treating patients hospitalized for COVID-19 with remdesivir was associated with a significantly lower likelihood of 30-day COVID-19-related readmission across all patients discharged alive from the initial COVID-19 hospitalization, including older adults and those with underlying immunocompromising conditions.

中文翻译：

---

瑞德西韦降低因 COVID-19 住院的脆弱患者 30 天再入院风险的有效性：一项使用倾向评分的美国回顾性队列研究


背景 减少再入院率为患者、提供者、支付方和政策制定者提供了潜在的好处，可以提高医疗保健质量、降低成本和改善患者体验。我们调查了瑞德西韦在 Omicron 时代减少 30 天 COVID-19 相关再入院的有效性，包括老年人和有潜在免疫功能低下疾病的人。方法 本回顾性研究利用美国 PINC AI 医疗保健数据库来确定 2021 年 12 月 1 日至 2024 年 2 月 29 日期间因指数 COVID-19 住院而活着出院的成年患者。在使用治疗加权逆概率 （IPTW） 平衡两组的特征后，比较接受瑞德西韦的患者与未接受瑞德西韦的患者之间 30 天 COVID-19 相关再入院的几率。分析按指数住院期间的最大补充氧气需求进行分层。结果 在研究期间因 COVID-19 住院的 326,033 名患者中，有 210,586 名患者符合资格标准。其中，109,551 例 （52%） 患者接受了瑞德西韦治疗。IPTW 后，在总人群（分别为 3.3% 和 4.2%;比值比 [95% 置信区间]：0.78 [0.75–0.80]）、老年人（分别为 3.7% 和 4.7%;0.78 [0.75–0.81]）和有潜在免疫功能低下疾病的患者（分别为 5.3% 和 6.2%;0.86 [0.80–0.92]）中观察到 30 天 COVID-19 相关再入院的几率较低。无论补充氧气需求如何，这些结果都是一致的。 结论 用瑞德西韦治疗因 COVID-19 住院的患者与所有从初始 COVID-19 住院中存活出院的患者（包括老年人和有潜在免疫功能低下的患者）的 30 天 COVID-19 相关再入院的可能性显着降低。